AN2 Therapeutics, Inc. (ANTX)
ANTX Stock Price Chart
Explore AN2 Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze ANTX price movements and trends.
ANTX Company Profile
Discover essential business fundamentals and corporate details for AN2 Therapeutics, Inc. (ANTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
25 Mar 2022
Employees
22.00
Website
https://www.an2therapeutics.comCEO
Eric E. Easom
Description
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.
ANTX Financial Timeline
Browse a chronological timeline of AN2 Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$0.23.
Earnings released on 11 May 2026
EPS came in at -$0.29 falling short of the estimated -$0.23 by -26.09%.
Earnings released on 17 Mar 2026
EPS came in at -$0.29 falling short of the estimated -$0.24 by -20.83%.
Earnings released on 12 Nov 2025
EPS came in at -$0.31 falling short of the estimated -$0.23 by -34.78%.
Earnings released on 12 Aug 2025
EPS came in at -$0.21 surpassing the estimated -$0.31 by +32.26%.
Earnings released on 13 May 2025
EPS came in at -$0.35 falling short of the estimated -$0.26 by -34.62%.
Earnings released on 25 Mar 2025
EPS came in at -$0.25 matching the estimated -$0.25.
Earnings released on 13 Nov 2024
EPS came in at -$0.43 falling short of the estimated -$0.37 by -16.22%.
Earnings released on 13 Aug 2024
EPS came in at -$0.48 surpassing the estimated -$0.63 by +23.81%.
Earnings released on 14 May 2024
EPS came in at -$0.56 surpassing the estimated -$0.61 by +8.20%.
Earnings released on 28 Mar 2024
EPS came in at -$0.57 surpassing the estimated -$0.71 by +19.72%, while revenue for the quarter reached $80.00k .
Earnings released on 9 Nov 2023
EPS came in at -$0.65 falling short of the estimated -$0.63 by -3.17%.
Earnings released on 10 Aug 2023
EPS came in at -$0.81 surpassing the estimated -$0.85 by +4.71%.
Earnings released on 11 May 2023
EPS came in at -$0.79 falling short of the estimated -$0.68 by -16.18%.
Earnings released on 29 Mar 2023
EPS came in at -$0.61 surpassing the estimated -$0.63 by +3.17%.
Earnings released on 9 Nov 2022
EPS came in at -$0.59 matching the estimated -$0.59.
Earnings released on 11 Aug 2022
EPS came in at -$0.53 falling short of the estimated -$0.45 by -17.78%.
Earnings released on 10 May 2022
EPS came in at -$2.98 falling short of the estimated -$0.52 by -473.08%.
Earnings released on 28 Mar 2022
EPS came in at -$0.49 .
Earnings released on 31 Dec 2021
EPS came in at -$0.42 .
ANTX Stock Performance
Access detailed ANTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
